Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-25 20:36 | 2026-03-23 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Director | SELL | $3.25 | 40,000 | $130,000 | 906,556 |
| 2026-03-25 20:05 | 2026-03-23 | VCEL | Vericel Corp | Hagen Heidi | Director | OPT+S | $32.41 | 15,000 | $486,150 | 31,850 |
| 2026-03-24 20:02 | 2026-03-20 | BCRX | BIOCRYST PHARMACEUTICALS INC | HEGGIE THERESA | Director | OPT+S | $10.11 | 49,933 | $504,823 | 65,352 |
| 2026-03-24 20:35 | 2026-03-23 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | Officer | SELL | $9.12 | 7,711 | $70,324 | 61,902 |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $43.79 | 354 | $15,500 | 137,903 |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Green Paula | Officer | SELL | $43.79 | 297 | $13,005 | 124,104 |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | SELL | $43.79 | 1,742 | $76,276 | 858,887 |
| 2026-03-25 01:12 | 2026-03-24 | MGTX | MeiraGTx Holdings plc | Forbes Alexandria | Director, Officer | SELL | $7.41 | 62,000 | $459,420 | 1,449,695 |
| 2026-03-24 22:30 | 2026-03-20 | FDMT | 4D Molecular Therapeutics, Inc. | Gupta Ashoo | Officer | OPT+S | $8.61 | 390 | $3,358 | 47,055 |
| 2026-03-24 21:37 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | Prasad Raju | Officer | OPT+S | $46.78 | 3,708 | $173,460 | 15,565 |
| 2026-03-24 21:37 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | Director, Officer | OPT+S | $46.78 | 10,020 | $468,736 | 255,501 |
| 2026-03-24 21:38 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | Officer | OPT+S | $46.78 | 3,182 | $148,854 | 94,308 |
| 2026-03-24 21:05 | 2026-03-20 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | Officer | SELL | $66.75 | 2,989 | $199,516 | 82,791 |
| 2026-03-23 20:05 | 2026-03-20 | KLRS | Kalaris Therapeutics, Inc. | Hagen Brett R | Officer | SELL | $6.72 | 1,915 | $12,869 | 0 |
| 2026-03-23 23:18 | 2026-03-19 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $13.46 | 57,180 | $769,643 | 481,906 |
| 2026-03-20 22:50 | 2026-03-20 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer | OPT+S | $49.10 | 15,000 | $736,440 | 0 |
| 2026-03-20 22:30 | 2026-03-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Director | OPT+S | $79.15 | 2,500 | $197,877 | 0 |
| 2026-03-20 20:54 | 2026-03-18 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.73 | 4,575 | $26,214 | 2,439,918 |
| 2026-03-20 20:11 | 2026-03-18 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | Officer | SELL | $24.97 | 2,877 | $71,839 | 147,053 |
| 2026-03-19 20:05 | 2026-03-17 | TWST | Twist Bioscience Corp | CHESS ROBERT | Director | OPT+S | $47.00 | 10,000 | $470,000 | 21,084 |
| 2026-03-19 23:03 | 2026-03-17 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Director, Officer | SELL | $68.34 | 34,603 | $2,364,904 | 33,421 |
| 2026-03-19 23:03 | 2026-03-17 | TARS | Tarsus Pharmaceuticals, Inc. | Farrow Jeffrey S | Officer | SELL | $68.36 | 6,430 | $439,566 | 43,316 |
| 2026-03-19 23:04 | 2026-03-17 | TARS | Tarsus Pharmaceuticals, Inc. | Lin Elizabeth Yeu | Officer | SELL | $68.36 | 1,144 | $78,204 | 23,308 |
| 2026-03-19 23:04 | 2026-03-17 | TARS | Tarsus Pharmaceuticals, Inc. | Mottiwala Aziz | Officer | SELL | $68.36 | 13,056 | $892,529 | 61,480 |
| 2026-03-19 23:04 | 2026-03-17 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | Officer | SELL | $68.21 | 11,324 | $772,444 | 85,780 |
| 2026-03-19 23:04 | 2026-03-17 | TARS | Tarsus Pharmaceuticals, Inc. | Wahl Bryan | Officer | SELL | $68.36 | 12,440 | $850,417 | 63,959 |
| 2026-03-19 23:04 | 2026-03-17 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | Officer | SELL | $68.36 | 12,274 | $839,069 | 35,028 |
| 2026-03-19 22:53 | 2026-03-17 | RVMD | Revolution Medicines, Inc. | Wang Xiaolin | Officer | SELL | $99.48 | 2,010 | $199,956 | 116,063 |
| 2026-03-19 22:54 | 2026-03-17 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | Officer | SELL | $98.68 | 2,958 | $291,890 | 58,518 |
| 2026-03-19 22:55 | 2026-03-17 | RVMD | Revolution Medicines, Inc. | Anders Jack | Officer | SELL | $99.48 | 2,753 | $273,870 | 125,512 |
| 2026-03-19 22:56 | 2026-03-17 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | Officer | SELL | $99.48 | 4,583 | $455,919 | 157,570 |
| 2026-03-19 22:56 | 2026-03-17 | RVMD | Revolution Medicines, Inc. | GOLDSMITH MARK A | Director, Officer | SELL | $99.48 | 12,871 | $1,280,412 | 276,698 |
| 2026-03-19 22:57 | 2026-03-17 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | Officer | SELL | $99.48 | 4,302 | $427,965 | 295,398 |
| 2026-03-19 22:57 | 2026-03-17 | RVMD | Revolution Medicines, Inc. | Wei Lin | Officer | SELL | $99.48 | 2,073 | $206,223 | 101,366 |
| 2026-03-18 21:00 | 2026-03-16 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | Officer | OPT+S | $6.74 | 708 | $4,768 | 9,099 |
| 2026-03-18 20:06 | 2026-03-16 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | Officer | SELL | $2.47 | 4,835 | $11,942 | 198,205 |
| 2026-03-18 20:05 | 2026-03-16 | ALLO | Allogene Therapeutics, Inc. | Chang David D | Director, Officer | SELL | $2.47 | 47,763 | $117,975 | 5,150,599 |
| 2026-03-18 22:55 | 2026-03-16 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.78 | 1,331 | $7,696 | 2,435,343 |
| 2026-03-18 23:03 | 2026-03-17 | PCVX | Vaxcyte, Inc. | Cowan Elvia | Officer | SELL | $55.57 | 1,892 | $105,147 | 28,975 |
| 2026-03-18 22:21 | 2026-03-16 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $13.33 | 57,180 | $762,209 | 494,920 |
| 2026-03-18 21:52 | 2026-03-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Taylor Ben R | Officer | SELL | $3.39 | 7,956 | $26,971 | 1,180,318 |
| 2026-03-18 21:47 | 2026-03-16 | PHGE | BiomX Inc. | Yeganeh Reuven | Director, 10% owner | SELL | $5.00 | 980,000 | $4,900,000 | 0 |
| 2026-03-18 20:11 | 2026-03-16 | BCRX | BIOCRYST PHARMACEUTICALS INC | Barnes Alane P | Officer | OPT+S | $9.15 | 150,000 | $1,372,500 | 400,703 |
| 2026-03-18 20:11 | 2026-03-16 | TARS | Tarsus Pharmaceuticals, Inc. | LINK WILLIAM J PHD | Director | SELL | $68.79 | 12,500 | $859,819 | 116,332 |
| 2026-03-17 20:29 | 2026-03-10 | TVGN | Tevogen Bio Holdings Inc. | Flomenberg Neal | Officer | SELL | $6.83 | 972 | $6,635 | 76,940 |
| 2026-03-17 20:15 | 2026-03-16 | CGON | CG Oncology, Inc. | Mulay James | Director | OPT+S | $63.50 | 1,964 | $124,714 | 0 |
| 2026-03-18 01:00 | 2026-03-16 | ADMA | ADMA BIOLOGICS, INC. | Grossman Adam S | Director, Officer | OPT+S | $15.16 | 21,000 | $318,360 | 2,112,777 |
| 2026-03-17 22:56 | 2026-03-16 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer | SELL | $144.23 | 3,000 | $432,690 | 131,779 |
| 2026-03-17 22:14 | 2026-03-16 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer | SELL | $144.23 | 3,000 | $432,690 | 179,191 |
| 2026-03-17 21:35 | 2026-03-16 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | Director, Officer | OPT+S | $48.26 | 10,349 | $499,443 | 245,834 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.